Universidad de Ciencias Médicas de La Habana, Playa, La Habana, Cuba; Instituto de Cardiología y Cirugía Cardiovascular, La Habana, Cuba.
Universidad de Ciencias Médicas de La Habana, Playa, La Habana, Cuba; Instituto de Cardiología y Cirugía Cardiovascular, La Habana, Cuba.
Clin Investig Arterioscler. 2021 Nov-Dec;33(6):314-322. doi: 10.1016/j.arteri.2021.02.013. Epub 2021 Apr 2.
Beyond glucemic control there are other important goals when it comes to providing integral care to patients with diabetes mellitus. A bibliographic review was made in order to identify the role played by new antidiabetic drugs in cardiovascular prevention and heart failure. The use of SLGT2i and GLP1a leads to a significant decrease in cardiovascular events, with no difference between the two, except when it comes to hospitalizations for heart failure, where the superiority of the last ones (especially dapaglifozin and empaglifozin) is evident. The current evidence regarding the effect of dpp-4i is diverse, although an increased risk of hospitalizations for heart failure is observed with the use of some drugs of this class (saxagliptin).
除了控制血糖之外，在为糖尿病患者提供全面护理方面还有其他重要目标。我们进行了文献复习，以确定新型抗糖尿病药物在心血管预防和心力衰竭方面的作用。使用 SGLT2i 和 GLP1a 可显著降低心血管事件的发生，两者之间没有差异，但心力衰竭住院治疗除外，最后一类药物（特别是达格列净和恩格列净）具有明显优势。目前关于 DPP-4i 效果的证据多种多样，尽管使用该类药物中的某些药物（沙格列汀）会增加心力衰竭住院的风险。
